Clinical Trial Update: A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® [Phase 4]

View source ↗

Summary

A Phase 4 trial updating OCT parameter changes in patients with Relapsing Remitting Multiple Sclerosis treated with Gilenya (fingolimod).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Remitting Multiple Sclerosis RRMS | Phase 4 | Status: COMPLETED | Results posted: 2020-03-02